Evidence map›Paper›PMID 29863746›Full record

ReviewBritish journal of clinical pharmacology2018

Long-term adverse effects of paracetamol - a review.

J C McCrae, E E Morrison, I M MacIntyre, J W Dear, D J Webb

Abstract readReview
In one paragraph

Review in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Observational
  19. Review
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

J C McCraeBHF Centre of Research Excellence (CoRE), Queen's Medical Research Institute, Pharmacology, Toxicology & Therapeutics, Edinburgh, UK.ORCID 0000-0002-1009-0404
E E MorrisonBHF Centre of Research Excellence (CoRE), Queen's Medical Research Institute, Pharmacology, Toxicology & Therapeutics, Edinburgh, UK.ORCID 0000-0003-4478-1550
I M MacIntyreBHF Centre of Research Excellence (CoRE), Queen's Medical Research Institute, Pharmacology, Toxicology & Therapeutics, Edinburgh, UK.ORCID 0000-0003-4420-3822
J W DearBHF Centre of Research Excellence (CoRE), Queen's Medical Research Institute, Pharmacology, Toxicology & Therapeutics, Edinburgh, UK.ORCID 0000-0002-8630-8625
D J WebbBHF Centre of Research Excellence (CoRE), Queen's Medical Research Institute, Pharmacology, Toxicology & Therapeutics, Edinburgh, UK.ORCID 0000-0003-0755-1756

Funding

British Heart Foundation PG/13/26/30128
6 · The paper itself

Abstract

Paracetamol (acetaminophen) is the most commonly used drug in the world, with a long record of use in acute and chronic pain. In recent years, the benefits of paracetamol use in chronic conditions has been questioned, notably in the areas of osteoarthritis and lower back pain. Over the same period, concerns over the long-term adverse effects of paracetamol use have increased, initially in the field of hypertension, but more recently in other areas as well. The evidence base for the adverse effects of chronic paracetamol use consists of many cohort and observational studies, with few randomized controlled trials, many of which contradict each other, so these studies must be interpreted with caution. Nevertheless, there are some areas where the evidence for harm is more robust, and if a clinician is starting paracetamol with the expectation of chronic use it might be advisable to discuss these side effects with patients beforehand. In particular, an increased risk of gastrointestinal bleeding and a small (~4 mmHg) increase in systolic blood pressure are adverse effects for which the evidence is particularly strong, and which show a degree of dose dependence. As our estimation of the benefits decreases, an accurate assessment of the harms is ever more important. The present review summarizes the current evidence on the harms associated with chronic paracetamol use, focusing on cardiovascular disease, asthma and renal injury, and the effects of in utero exposure.

Indexed as

AcetaminophenAcute Kidney InjuryAnalgesics, Non-NarcoticAsthmaCardiovascular DiseasesChronic PainFemaleHumansIncidenceLong-Term CareMaternal ExposureNeurodevelopmental DisordersObservational Studies as TopicPractice Guidelines as TopicPregnancyPrenatal Exposure Delayed EffectsAcetaminophenAnalgesics, Non-Narcoticacetaminophenadverse effectsasthmagastrointestinal bleedinghypertensionkidney disease

Identifiers

PMID29863746
PMCPMC6138494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.